Related references
Note: Only part of the references are listed.Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry)
Kohjiro Ueki et al.
BMJ OPEN DIABETES RESEARCH & CARE (2021)
Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes
Chen Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
The safety of gliptins : updated data in 2018
Andre Jacques Scheen
EXPERT OPINION ON DRUG SAFETY (2018)
Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men
Saori Tsuchiya et al.
JOURNAL OF DIABETES INVESTIGATION (2017)
Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus
S. Del Prato et al.
DIABETES OBESITY & METABOLISM (2016)
Omarigliptin for the treatment of type 2 diabetes mellitus
Philip M. S. Evans et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy Subjects
Rajesh Krishna et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
LC-tandem mass spectrometry method for the simultaneous determination of metformin and sitagliptin in human plasma after ion-pair solid phase extraction
Priyanka A. Shah et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2016)
Beat diabetes: an urgent call for global action
[Anonymous]
LANCET (2016)
Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism
Charles E. Grimshaw et al.
PLOS ONE (2016)
Current prevalence of Type 1 and Type 2 diabetes in adults and children in the UK
N. Holman et al.
DIABETIC MEDICINE (2015)
Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study
Shinichi Umezawa et al.
BMC ENDOCRINE DISORDERS (2015)
A Rapid and Sensitive LC-MS/MS Assay for the Determination of Saxagliptin and its Active Metabolite 5-hydroxy Saxagliptin in Human Plasma and its Application to a Pharmacokinetic Study
N. Batta et al.
DRUG RESEARCH (2015)
Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes
Tesfaye Biftu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans
Stella H. Vincent et al.
DRUG METABOLISM AND DISPOSITION (2007)
Matrix effects: The Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry
PJ Taylor
CLINICAL BIOCHEMISTRY (2005)
Share Paper
